Sartorius AG
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG000BGC542
SRT3
Sartorius AG
GICS: 35203010
·
Sector: Laboratory equipment
·
Sub-Sector: -
NAME
Sartorius AG
ISIN
DE0007165631
TICKER
SRT3
MIC
XETR
REUTERS
SATG_p.DE
BLOOMBERG
SRT3 GR
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Mon, 17.02.2025
Göttingen, Germany | February 17, 2025
Sartorius releases Annual Report for 2024
The life science group Sartorius today released its Annual Report for 2024. The document is available at the following link: https://ir-reports.sartorius.com/en/ag/fy-2024/
Financial calendar
March 27, 2025 Annual Shareholders’ Meeting
April 16, 2025...
Fri, 07.02.2025
Göttingen, February 7, 2025
The Supervisory Board of Sartorius AG proposes
a dividend of 0.74 euros per preference share
The Supervisory Board of Sartorius AG resolved at its meeting today to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of 0.74 euros p...
Tue, 28.01.2025
Göttingen, Germany | January 28, 2025
Sartorius closes fiscal 2024 with very good fourth quarter and positive trend; full-year guidance achieved
Preliminary business results for 2024: sales revenue at 3,381 million euros (+ 0.1 percent in constant currencies), underlying profit margin reaches 28.0 percent
Order intake + 10.8 percent, demand i...
Fri, 06.12.2024
Göttingen, December 6, 2024
Michael Grosse to succeed Joachim Kreuzburg as Chief Executive Officer of Sartorius AG
Grosse to take over as Group CEO on July 1, 2025
At its meeting today, the Supervisory Board of Sartorius AG appointed Dr. Michael Grosse Chief Executive Officer of Sartorius. He will take over this position on July 1, 2025, from D...
Fri, 06.12.2024
Disclosure of inside information according to Article 17 MAR
Michael Grosse to become Chief Executive Officer of Sartorius AG
At its meeting today, the Supervisory Board of Sartorius AG resolved to appoint Dr. Michael Grosse as member of the Executive Board and Chief Executive Officer of the company with effect from July 1, 2025, for a term of th...
Thu, 17.10.2024
Göttingen, Germany | October 17, 2024
Nine-month results in line with expectations: sales revenue almost at prior-year level; orders on the rise; robust profitability; increased cash flow
Group sales revenue down only slightly by - 2.0 percent after nine months; order intake up 6.6 percent
Underlying EBITDA margin reaches 27.7 percent; further i...
Thu, 18.07.2024
Göttingen, July 18, 2024
Half-year results: Moderately positive revenue development in the second quarter; demand recovery remains muted, full-year outlook deliberately more cautious; long-term trends remain positive
Sales revenue slightly down 2.2 percent after six months; growth of 3.6 percent in second quarter
Underlying EBITDA margin at a ...
Thu, 18.07.2024
Disclosure of inside information according to Article 17 MAR
Sartorius AG adjusts its guidance for fiscal year 2024 and presents results for H1 2024
In a continuously very challenging and volatile market environment, the life science group Sartorius closed the first half of the year with a positive trend in sales revenue development. In view of t...
Information on product placements
SMART * AD
P R O D U C T S U G G E S T I O N S
